What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Demark's Pivot Points

Score

-0.7

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 99 4.0 0.39% 0.54% 9.6% -3.3% 137.2%
SHORT 99 5.3 0.41% 0.59% 3.4% -3.6% -109.4%

Summary

Technical Analysis

Opthea (OPT.AX)


Indicator:

DEMARK PIVOT POINT


Signal Strength: MEDIUM
Recommendation:

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading position.


Opthea (ASX:OPT) current pivot point (DeMark) is:
(R1) $1.848.

The current pivot point (DeMark) is:
(S1) $1.668.



Demark Pivot Points start with a different base and use different formulas for support and resistance. These Pivot Points are conditional on the relationship between the close and the open.

Calculation: Demarks Pivot Points:
1) If Close < Open then X = High + (2 x Low) + Close;
2) If Close > Open then X = (2 x High) + Low + Close;
3) If Close = Open then X = High + Low + (2 x Close) ;
4) Pivot Point (P) = X/4;
5) Support 1 (S1) = X/2 – High;
6) Resistance 1 (R1) = X/2 – Low;


PROFILE: Opthea (OPT.AX)


Stock Exchange: ASX
Company: Opthea
Ticker Codes: | OPT.AX | ASX:OPT |

About Opthea (ASX:OPT):

Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trial for the treatment of back of the eye diseases, such as wet age-related macular degeneration that is the cause of blindness in elderly and diabetic populations. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.

Top 10:

Demark's Pivot Points

Download
Company Close Change(%) Volume Value Signal
MNS Milnes Holdings 0.07 16.4 1,475,601 0 BULLISH
BKY Berkeley Resources 0.16 14.3 563,400 0 BULLISH
VTG Vita 0.69 7.8 665,880 0.01 BULLISH
ALQ ALS 5.39 5.5 3,572,301 0.03 BULLISH
IMD Imdex 0.89 4.7 3,098,591 0.01 BULLISH
SDG Sunland 1.16 4.5 26,273 0 BULLISH
CUV Clinuvel Pharmaceuticals 18.89 4.4 263,447 0.1 BULLISH
SNZ Summerset Holdings 5.49 3.8 1,100 0.04 BULLISH
MLD Maca 0.62 2.5 465,837 0.02 BULLISH
NAN Nanosonics 5.34 2.5 2,744,195 0.07 BULLISH